6541
vs
T
Taiwan Weighted Index
6541
Over the past 12 months, Tanvex BioPharma Inc has underperformed Taiwan Weighted Index, delivering a return of -37% compared to the Taiwan Weighted Index's +54% growth.
Stocks Performance
6541 vs Taiwan Weighted Index
Performance Gap
6541 vs Taiwan Weighted Index
Performance By Year
6541 vs Taiwan Weighted Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Tanvex BioPharma Inc
Glance View
Tanvex BioPharma, Inc. operates as clinical stage company, which engages in the research and development, production, and sale of pharmaceutical products. The firm is also engaged in areas of strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing and warehousing, sales and distribution. The Company’s product pipeline includes Neupogen (TX-01), TX-05, TX-04, TX-16, TX-52, and others. The firm offers a vertically integrated manufacturing platform for biopharmaceuticals. By controlling the entire process from research and development (R&D) and cell-line development. The firm is developing and delivering biologic and biosimilar drugs to the people.
